• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Centessa Pharmaceuticals plc

    3/25/25 4:09:32 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CNTA alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001400975
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Centessa Pharmaceuticals plc
    SEC File Number
    001-40445
    Address of Issuer
    3RD FLOOR
    1 ASHLEY ROAD
    ALTRINCHAM, CHESHIRE
    UNITED KINGDOM
    WA14 2DT
    Phone
    44 7391 789784
    Name of Person for Whose Account the Securities are To Be Sold
    Weinhoff Gregory M
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    UBS Financial Services, Inc
    1000 Harbor Blvd
    3rd Floor
    Weehawken � NJ � 07086
    10000165300.0013318434903/25/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common03/25/2025Exercise of stock optionsIssuerCheckbox not checked1000003/25/2025CASH

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Gregory Weinhoff
    3rd Floor
    1 Ashley Road
    Altrincham, Cheshire � X0 � WA14 2DT
    Common12/26/202410000170399.00
    Gregory Weinhoff
    3rd Floor
    1 Ashley Road
    Altrincham, Cheshire � X0 � WA142DT
    Common01/27/202511742193429.49
    Gregory Weinhoff
    3rd Floor
    1 Ashley Road
    Altrincham, Cheshire � X0 � WA14 2DT
    Common02/25/202511494175269.71

    144: Remarks and Signature

    Remarks
    The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan.
    Date of Notice
    03/25/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    05/22/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ UBS Financial Services Inc, as attorney-in-fact for Gregory Weinhoff

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $CNTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CNTA

    DatePrice TargetRatingAnalyst
    5/8/2025$30.00Buy
    Chardan Capital Markets
    3/31/2025$38.00Overweight
    Piper Sandler
    1/7/2025Buy
    TD Cowen
    9/20/2024$11.00 → $26.00Equal-Weight → Overweight
    Morgan Stanley
    9/19/2024$33.00Buy
    B. Riley Securities
    7/18/2024$14.00Outperform
    Oppenheimer
    11/15/2023$4.00 → $11.00Hold → Buy
    Jefferies
    10/26/2023$4.00 → $8.00Underweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $CNTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on Centessa Pharmaceuticals with a new price target

      Chardan Capital Markets initiated coverage of Centessa Pharmaceuticals with a rating of Buy and set a new price target of $30.00

      5/8/25 8:28:10 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Centessa Pharmaceuticals with a new price target

      Piper Sandler initiated coverage of Centessa Pharmaceuticals with a rating of Overweight and set a new price target of $38.00

      3/31/25 8:13:04 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on Centessa Pharmaceuticals

      TD Cowen initiated coverage of Centessa Pharmaceuticals with a rating of Buy

      1/7/25 7:47:10 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc

      SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)

      11/14/24 5:43:48 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc

      SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)

      11/14/24 4:20:32 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc (Amendment)

      SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)

      2/14/24 5:37:34 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTA
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Centessa Pharmaceuticals plc

      DEF 14A - Centessa Pharmaceuticals plc (0001847903) (Filer)

      5/6/25 9:00:14 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Centessa Pharmaceuticals plc

      144 - Centessa Pharmaceuticals plc (0001847903) (Subject)

      4/25/25 4:12:30 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Centessa Pharmaceuticals plc

      PRE 14A - Centessa Pharmaceuticals plc (0001847903) (Filer)

      4/22/25 4:59:12 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTA
    Financials

    Live finance-specific insights

    See more
    • Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023

      SerpinPC: Ongoing registrational PRESent-2 and PRESent-3 studies for the treatment of hemophilia B; New data from ongoing Phase 2a study accepted for poster presentation at American Society of Hematology (ASH) Annual Meeting in December 2023 ORX750: Preclinical data supporting potential best-in-class profile for the treatment of narcolepsy and other sleep-wake disorders presented at World Sleep Congress; Advancing in IND-enabling studies; Clinical proof of concept data planned for 2024LockBody® Technology Platform: Ongoing Phase 1/2a study of LB101 (PD-L1xCD47) for the treatment of solid tumors BOSTON and LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA

      11/13/23 4:05:10 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023

      Enrollment and dosing ongoing in registrational study of SerpinPC for the treatment of hemophilia BEnrollment and dosing ongoing in Phase 1/2a Study of LB101, a PD-L1xCD47 LockBody® for the treatment of solid tumors IND-enabling activities advancing for ORX750, an oral selective orexin receptor 2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; Announces ORX750 preclinical data to be presented at World Sleep Congress in October 2023 Nominates second LockBody candidate, LB206, a conditionally bivalent PD-L1xCD3 bispecific monoclonal antibody BOSTON and LONDON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceuti

      8/14/23 7:00:30 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023

      – Strong clinical momentum and cash runway into 2026 to support multiple clinical readouts across pipeline – Advancing registration program for SerpinPC to treat hemophilia B; Enrolling subjects in PRESent-5, observational feeder study Dosing subjects in ongoing Phase 1/2a clinical trial for LB101, a PD-L1xCD47 LockBody® to treat solid tumorsConducting IND enabling activities for ORX750, an orally administered, selective orexin receptor 2 (OX2R) agonist, with the potential to be a best-in-class therapy to treat narcolepsy and other sleep disorders; ORX750 profile to be presented at scientific meeting in 2023 BOSTON and LONDON, May 12, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals

      5/12/23 7:00:06 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

      Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025 ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) well underway and on track with data expected across all three indications in 2025 with first-in-class potential in NT2 and IHORX142 in IND-enabling studies for the treatment of neurological and neurodegenerative disorders; Clinical data in acutely sleep-deprived healthy volunteers planned for 2025ORX489 in IND-enabling studies for the treatment of neuropsychiatric disorders BOSTON and LONDON, March 24, 2025 (GLOBE NEWSWIRE) -- Cent

      3/24/25 7:00:49 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

      BOSTON and LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that data from the Phase 1 clinical trial of ORX750, an investigational novel highly potent and selective OX2R agonist being progressed for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), will be presented in a poster session at the American Academy of Neurology (AAN) 2025 Annual Meeting being held April 5-9, 2025, in San Diego, CA. ORX750 is being evaluated in an ongoing Phase 2a clinical trial (CRYSTAL-1

      3/6/25 4:14:40 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

      BOSTON and LONDON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim SMID Cap Biotech Conference Date: February 6, 2025Fireside Chat: 1:00 PM ET Event: Oppenheimer 35th Annual Healthcare Life Sciences Conference Date: February 12, 2025Fireside Chat: 10:40 AM ET Event: TD Cowen 45th Annual Health Care ConferenceDate: March 4, 2025Fireside Chat: 1:50 PM ET Event: Leerink Partners Global Healthcare ConferenceDate: March 11,

      1/28/25 8:00:00 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTA
    Leadership Updates

    Live Leadership Updates

    See more
    • Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

      BOSTON and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today announced the appointment of Stephen Kanes MD PhD, as Chief Medical Officer (CMO). Dr. Kanes is a neuropsychiatrist, with a career in neuroscience, clinical psychiatry, and neuroscience drug development spanning more than 30 years.  "Centessa is rapidly advancing a potential best-in-class and first-in-class portfolio of orexin receptor 2 (OX2R) agonists with a robust series of clinical milestones anticipated this year," said Saurabh Saha MD

      1/8/25 7:05:00 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer

      BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Financial Officer, and Gregory Weinhoff MD MBA, former Chief Financial Officer, has been appointed to the newly created role of Chief Business Officer, effective June 10, 2024. "With all three of our core programs in the clinic, we believe we have solidified a strong foundation and are poised for our next exciting chapter as a company. To best position Centessa for this pivotal time, we've added key new talen

      6/10/24 7:00:00 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Centessa Pharmaceuticals Announces Additions to Senior Leadership Team

      BOSTON and LONDON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the appointment of April Dovholuk and Ellie Im, MD to Centessa's executive team as Senior Vice President of Development Operations and Senior Vice President of Clinical Development, Oncology, respectively. In these newly created roles, Ms. Dovholuk will lead both Centessa's global Clinical Trials and Development Operations teams, and Dr. Im will manage clinical development of the Company's Oncology programs based on the LockBody® technology platform. "We a

      10/3/23 8:00:00 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • General Counsel Hussain Iqbal J exercised 311 units of Ordinary Shares at a strike of $5.84 and sold $4,354 worth of Ordinary Shares (311 units at $14.00) (SEC Form 4)

      4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)

      5/2/25 4:17:05 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Hussain Iqbal J exercised 5,689 units of Ordinary Shares at a strike of $5.84 and sold $79,658 worth of Ordinary Shares (5,689 units at $14.00) (SEC Form 4)

      4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)

      4/29/25 4:58:03 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Business Officer Weinhoff Gregory M sold $159,857 worth of Ordinary Shares (11,742 units at $13.61), decreasing direct ownership by 9% to 122,279 units (SEC Form 4)

      4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)

      4/25/25 8:20:27 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care